Your browser doesn't support javascript.
loading
Progress of chimeric antigen receptor T-cell therapy for multiple myeloma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma ; (12): 136-140, 2020.
Article in Chinese | WPRIM | ID: wpr-862810
ABSTRACT
Chimeric antigen receptor T-cell (CAR-T) therapy has made a breakthrough in the treatment of hematological tumors. CAR-T therapy targeting kappa immunoglobulin light chain, CD19 and B-cell mature antigen (BCMA) have been used to treat relapsed/refractory MM (RRMM) patients, and the effect of anti-BCMA CAR-T is the best. However, the negative or positive recurrence of BCMA leads to a short progression-free survival (PFS), the improvement of the chimeric antigen receptor (CAR) structure targeted BCMA, dual-targeted CAR-T and CAR-T combined with small molecular drugs as well as other measures have become the focuses of CAR-T in the treatment of RRMM.
Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Journal of Leukemia & Lymphoma Year: 2020 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Journal of Leukemia & Lymphoma Year: 2020 Type: Article